원료의약품(API) 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of Active Pharmaceutical Ingredient (API) Market

The global Active Pharmaceutical Ingredient (API) market was valued at USD 245.26 billion in 2025 and is projected to grow to USD 261.28 billion in 2026. The market is expected to reach USD 457.75 billion by 2034, exhibiting a CAGR of 7.26% during the forecast period (2026-2034).

North America dominated the global market with a 47.22% share in 2025, driven by high demand for innovative drugs and increasing prevalence of chronic diseases.

Market Overview

Active Pharmaceutical Ingredients (APIs), also known as bulk drugs, are the key components responsible for the therapeutic effects of medicines. They are produced through chemical or biological processes and form the backbone of pharmaceutical formulations.

The market is witnessing steady growth due to rising demand for advanced therapeutics, increasing focus on personalized medicine, and continuous innovations by pharmaceutical and biotechnology companies. Additionally, the growing adoption of novel drug delivery systems is further strengthening the demand for APIs globally.

Impact of COVID-19

The COVID-19 pandemic had a negative impact on the API market initially due to factory shutdowns, especially in China, and disruptions in raw material supply chains. Reduced demand for elective procedures also affected pharmaceutical consumption.

However, the market rebounded post-pandemic due to strong demand for life-saving drugs, particularly respiratory medicines, and the reopening of manufacturing facilities worldwide.

Market Trends

Rising Outsourcing of API Manufacturing

One of the key trends in the market is the increasing outsourcing of API production to countries such as China and India. Pharmaceutical companies are shifting away from in-house manufacturing to reduce costs and focus more on drug discovery and development.

Contract Development and Manufacturing Organizations (CDMOs) are gaining importance as they offer specialized expertise, infrastructure, and scalability, thereby boosting market growth.

Market Drivers

Growing Demand for Pharmaceuticals

The rising global burden of chronic diseases such as cancer, cardiovascular disorders, and diabetes is significantly increasing the demand for pharmaceutical drugs, thereby driving the API market.

In addition, growing healthcare expenditure and improved diagnosis rates in emerging economies are expanding the patient pool, leading to higher demand for both generic and branded drugs.

Increasing Demand for Biologics

The shift toward biologics and biosimilars is another major growth driver. Biological APIs are gaining traction due to their effectiveness in treating complex diseases, supported by increasing regulatory approvals and innovation in biotechnology.

Market Restraints

Price Fluctuations and Regulatory Challenges

Unpredictable pricing policies in emerging markets and dependency on limited suppliers for raw materials can hinder market growth. Sudden price hikes and supply chain disruptions pose challenges for manufacturers.

Additionally, stringent regulatory requirements across different regions make API production and approvals complex and time-consuming.

Segmentation Analysis

By Type

The branded API segment dominated the market with a 62.10% share in 2026, driven by strong R&D investments and innovation in high-potency drugs.

However, the generic API segment is expected to grow rapidly due to patent expirations and increasing demand for cost-effective medicines.

By Synthesis

The synthetic API segment led the market with a 70.52% share in 2026, owing to lower production costs and simpler manufacturing processes.

Meanwhile, biological APIs are projected to grow at a faster rate due to rising demand for advanced biologic therapies.

Regional Insights

North America

North America generated USD 115.81 billion in 2025 and is expected to reach USD 122.74 billion in 2026. Growth is driven by high prevalence of chronic diseases and strong R&D investments.

Europe

Europe accounted for USD 56.78 billion in 2025 and is projected to reach USD 60.61 billion in 2026, supported by increasing pharmaceutical production and research initiatives.

Asia Pacific

Asia Pacific held USD 53.35 billion in 2025 and is expected to grow to USD 57.31 billion in 2026. The region is the fastest-growing due to low manufacturing costs and strong outsourcing trends.

Rest of the World

This region was valued at USD 19.32 billion in 2025 and is projected to reach USD 20.61 billion in 2026, driven by improving infrastructure and regulatory developments.

Competitive Landscape

The API market is highly fragmented with key players such as AbbVie Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Amgen Inc., Cipla Inc., and Sun Pharmaceutical Industries Ltd.

These companies focus on strategic partnerships, acquisitions, and expansion of manufacturing capabilities to strengthen their global presence.

Conclusion

In conclusion, the global API market is set for steady and sustained growth, rising from USD 245.26 billion in 2025 to USD 457.75 billion by 2034. The growth is primarily driven by increasing demand for pharmaceuticals, rising chronic disease burden, and expanding biologics segment.

Despite challenges such as pricing volatility and regulatory complexities, the market presents strong opportunities through outsourcing, technological advancements, and growth in emerging economies. The shift toward biologics and personalized medicine will further shape the future of the API industry, making it a critical pillar of global healthcare development.

Segmentation

By Type

• Generic API
• Branded API

By Synthesis

• Biological API
• Synthetic API

By Geography

• North America (By Type, By Synthesis, and By Country)
  • U.S.
  • Canada
• Europe (By Type, By Synthesis, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, By Synthesis, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of World (By Type, and By Synthesis)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Chronic Diseases, By Key Countries/Regions, 2025
• 4.2. Key Industry Developments - Partnerships, Mergers, And Acquisitions
• 4.3. Therapeutic Applications of the Different Types of Active Pharmaceutical Ingredient
• 4.4. Impact of COVID-19 on the Market

5. Global Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Generic API
  • 5.1.2. Branded API
• 5.2. Market Analysis, Insights and Forecast - By Synthesis
  • 5.2.1. Biological API
  • 5.2.2. Synthetic API
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of World

6. North America Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Generic API
  • 6.1.2. Branded API
• 6.2. Market Analysis, Insights and Forecast - By Synthesis
  • 6.2.1. Biological API
  • 6.2.2. Synthetic API
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Generic API
  • 7.1.2. Branded API
• 7.2. Market Analysis, Insights and Forecast - By Synthesis
  • 7.2.1. Biological API
  • 7.2.2. Synthetic API
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Generic API
  • 8.1.2. Branded API
• 8.2. Market Analysis, Insights and Forecast - By Synthesis
  • 8.2.1. Biological API
  • 8.2.2. Synthetic API
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Rest of World Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Generic API
  • 9.1.2. Branded API
• 9.2. Market Analysis, Insights and Forecast - By Synthesis
  • 9.2.1. Biological API
  • 9.2.2. Synthetic API

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Teva Pharmaceutical Industries Ltd
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & Services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. AbbVie Inc.
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & Services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Abbott
    • 10.2.3.1. Overview
    • 10.2.3.2. Products & Services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Aurobindo Pharma
    • 10.2.4.1. Overview
    • 10.2.4.2. Products & Services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Cipla Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products & Services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Dr. Reddy's Laboratories Ltd
    • 10.2.6.1. Overview
    • 10.2.6.2. Products & Services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Sun Pharmaceutical Industries Ltd
    • 10.2.7.1. Overview
    • 10.2.7.2. Products & Services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Amgen Inc.
    • 10.2.8.1. Overview
    • 10.2.8.2. Products & Services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Biocon
    • 10.2.9.1. Overview
    • 10.2.9.2. Products & Services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)
  • 10.2.10. Mylan N.V.
    • 10.2.10.1. Overview
    • 10.2.10.2. Products & Services
    • 10.2.10.3. SWOT Analysis
    • 10.2.10.4. Recent Developments
    • 10.2.10.5. Strategies
    • 10.2.10.6. Financials (Based on Availability)